Point Therapeutics to Present at the New York RedChip Investor Conference
14 August 2006 - 9:00PM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the New York RedChip Investor
Conference at the Hilton New York in New York City on Tuesday,
August 15, 2006 at 11:30 a.m., Eastern Time. Mr. Kiepert will
review key research and development accomplishments and discuss
upcoming corporate initiatives. A live Web cast of the presentation
will be available on the Company's Web site, www.pther.com. About
Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical
company developing a portfolio of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. Point is currently studying its lead product candidate,
talabostat, in two Phase 3 double blind placebo-controlled trials
in non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic
leukemia, and in combination with gemcitabine in metastatic
pancreatic cancer. In addition, Point's portfolio includes two
other DPP inhibitors in preclinical development--PT-630 for type 2
diabetes, and PT-510 as a vaccine adjuvant.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles